Search research articles
Contact Us
Filters
Showing results (71-80 of 94) with videos related to
Page
of 10
Sort By:
The Lancet. Microbe
|
October 7, 2021
Radiological and functional evidence of the bronchial spread of tuberculosis: an observational analysis
Ray Y Chen, Xiang Yu, Bronwyn Smith, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
March 11, 2024
Pharmacokinetic-Pharmacodynamic Evidence From a Phase 3 Trial to Support Flat-Dosing of Rifampicin for Tuberculosis
Huy X Ngo, Ava Y Xu, Gustavo E Velásquez, et al.
The Lancet. Respiratory Medicine
|
January 28, 2014
Whole-genome sequencing to establish relapse or re-infection with Mycobacterium tuberculosis: a retrospective observational study
Josephine M Bryant, Simon R Harris, Julian Parkhill, et al.
Emerging Infectious Diseases
|
March 2, 2025
Efficacy and Safety of 4-Month Rifapentine-Based Tuberculosis Treatments in Persons with Diabetes
Ekaterina V Kurbatova, William C Whitworth, Lakshmi Praveena Peddareddy, et al.
Open Forum Infectious Diseases
|
July 9, 2025
Virology Outcomes of Tenofovir-lamivudine-dolutegravir in Treatment-naïve and Virologically Suppressed Individuals Switching From an NNRTI-based Regimen: An Observational Analysis at 13 Sites
Cissy Kityo, Caitlyn McCarthy, Serena P Koenig, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
August 30, 2022
Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349)
April C Pettit, Patrick P J Phillips, Ekaterina Kurbatova, et al.
The Lancet. Microbe
|
January 10, 2025
Safety, bactericidal activity, and pharmacokinetics of the antituberculosis drug candidate BTZ-043 in South Africa (PanACEA-BTZ-043-02): an open-label, dose-expansion, randomised, controlled, phase 1b/2a trial
Norbert Heinrich, Veronique de Jager, Julia Dreisbach, et al.
Emerging Infectious Diseases
|
January 6, 2026
Pregnancy Outcomes after Exposure to Tuberculosis Treatment in Phase 3 Clinical Trial, 2016-2020
Ekaterina V Kurbatova, William C Whitworth, Kia E Bryant, et al.
American Journal of Respiratory and Critical Care Medicine
|
January 7, 2017
Safety and Immunogenicity of Adenovirus 35 Tuberculosis Vaccine Candidate in Adults with Active or Previous Tuberculosis. A Randomized Trial
Richard N van Zyl-Smit, Aliasgar Esmail, Mary E Bateman, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
May 25, 2023
1-Year Incidence of Tuberculosis Infection and Disease Among Household Contacts of Rifampin- and Multidrug-Resistant Tuberculosis
Sonya Krishnan, Xingye Wu, Soyeon Kim, et al.
Page
of 10
Search research articles
Search
Showing results (71-80 of 94) with videos related to
Sort By:
Page
of 10
The Lancet. Microbe
|
October 7, 2021
Radiological and functional evidence of the bronchial spread of tuberculosis: an observational analysis
Ray Y Chen, Xiang Yu, Bronwyn Smith, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
March 11, 2024
Pharmacokinetic-Pharmacodynamic Evidence From a Phase 3 Trial to Support Flat-Dosing of Rifampicin for Tuberculosis
Huy X Ngo, Ava Y Xu, Gustavo E Velásquez, et al.
The Lancet. Respiratory Medicine
|
January 28, 2014
Whole-genome sequencing to establish relapse or re-infection with Mycobacterium tuberculosis: a retrospective observational study
Josephine M Bryant, Simon R Harris, Julian Parkhill, et al.
Emerging Infectious Diseases
|
March 2, 2025
Efficacy and Safety of 4-Month Rifapentine-Based Tuberculosis Treatments in Persons with Diabetes
Ekaterina V Kurbatova, William C Whitworth, Lakshmi Praveena Peddareddy, et al.
Open Forum Infectious Diseases
|
July 9, 2025
Virology Outcomes of Tenofovir-lamivudine-dolutegravir in Treatment-naïve and Virologically Suppressed Individuals Switching From an NNRTI-based Regimen: An Observational Analysis at 13 Sites
Cissy Kityo, Caitlyn McCarthy, Serena P Koenig, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
August 30, 2022
Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349)
April C Pettit, Patrick P J Phillips, Ekaterina Kurbatova, et al.
The Lancet. Microbe
|
January 10, 2025
Safety, bactericidal activity, and pharmacokinetics of the antituberculosis drug candidate BTZ-043 in South Africa (PanACEA-BTZ-043-02): an open-label, dose-expansion, randomised, controlled, phase 1b/2a trial
Norbert Heinrich, Veronique de Jager, Julia Dreisbach, et al.
Emerging Infectious Diseases
|
January 6, 2026
Pregnancy Outcomes after Exposure to Tuberculosis Treatment in Phase 3 Clinical Trial, 2016-2020
Ekaterina V Kurbatova, William C Whitworth, Kia E Bryant, et al.
American Journal of Respiratory and Critical Care Medicine
|
January 7, 2017
Safety and Immunogenicity of Adenovirus 35 Tuberculosis Vaccine Candidate in Adults with Active or Previous Tuberculosis. A Randomized Trial
Richard N van Zyl-Smit, Aliasgar Esmail, Mary E Bateman, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
May 25, 2023
1-Year Incidence of Tuberculosis Infection and Disease Among Household Contacts of Rifampin- and Multidrug-Resistant Tuberculosis
Sonya Krishnan, Xingye Wu, Soyeon Kim, et al.
Page
of 10